Streetwise Reports' Article Archives — November%202022 back to current month (220)
Pharma's Promising Path in COPD Treatment (04/26/2024)
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock.
AI Healthcare Stock Has Bullish Setup, Expert Says (04/22/2024)
Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy.
PDUFA Date Coming Up for U.K. Biopharma (04/22/2024)
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
Biopharma's New Drug for COPD Likely to be Approved (04/22/2024)
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
New AI Solutions Set To Transform Medical Education and Clinical Practice (04/19/2024)
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).
Analyst Says Pharma Co. Has No True Competitor (04/19/2024)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
LA Biotech's Lower Revenue Will Be Short Lived (04/17/2024)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
Healthcare Co. Welcomes Possible AI Funding Effort in Canada (04/09/2024)
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.
Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out (04/08/2024)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
Co. Adding 500 Patients to Its Mental Health Care Platform (04/03/2024)
This Canada-based health care technology firm is profitable and growing. Learn more about it here.
Analyst Encouraged by ON Gov's Decision To Sustain Fees (04/02/2024)
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
AI Co. Funded To Develop AI Approach to Health Equity (03/27/2024)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
AI Medical App Passes Standard Student Test (03/26/2024)
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector.
Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says (03/26/2024)
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.
Biotech Co.'s Target Price Significantly Higher Than Current (03/19/2024)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
Biotech Stocks Break Out (03/19/2024)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
Is This Pharma Set To Break Out After COPD Drug Approval? (03/15/2024)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024.
This Biotech Is a Potential Disruptor, Expert Says (03/12/2024)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy.
Wellness Co.'s New Initiatives Should 'Lower Barriers' Analysts Say (03/12/2024)
The Beachbody Company Inc.'s 4Q23 results have Roth MKM analysts maintaining their Buy rating.
Safe Supply Firm Announces Another Promising Acquisition (03/11/2024)
Safe Supply Streaming Co. adds another company to its portfolio, and continues advocating for harm reduction in the psychedelic sector.
Healthcare AI Firm Has 'Bright Future,' Analyst Predicts (03/08/2024)
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade.
NY Biotech Has Potentially Game Changing Anxiety Therapy (03/07/2024)
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.
Bionic Medical Co. Has Sufficient Funds to Operate Through 2024 (03/05/2024)
Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co.
'Safe Supply' Co. Secures Legal Flow of Coca Products (02/20/2024)
This is a milestone for the venture capital firm investing in efforts that address the toxic drug crisis in Canada and the U.S. Learn more about the company and the latest wave of drug reform.
Alt-Pharma VC adds 7% Stake in Testing Strip Firm (02/15/2024)
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio.
Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says (02/12/2024)
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly.
Wellness Co. Preparing for US Legislation (02/12/2024)
Wellness company Canopy Growth Corp. is taking steps forward while it waits for the U.S. to make legislative changes, according to a Roth MKM research note.
Drug Reformer Subsidiary Inspected for Dealer License (02/02/2024)
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances.
Leadership Cuts Won't Slow This Biotech (01/26/2024)
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.
Pharma Co. Primed for Future Business (01/25/2024)
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development.
Healthcare Co. Exceeds Expectations in Performance (01/24/2024)
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.
Innovator in Drug Policy Now Listed on the OTCQBA Venture Market (01/18/2024)
Safe Supply Streaming Co. Ltd. Announced that it is expanding availability for potential investors. Read on to see why this stock might represent an opportunity as drug policy changes.
Pharma Co. Invests in Clinical Psychedelics (01/17/2024)
ATAI Life Sciences N.V. has announced that it is investing in psychedelic treatments for Major Depressive Disorder and Alcohol Use Disorder. Read on to see why one analyst likes this company's stock.
Money Manager: The Year of Small Caps? (01/16/2024)
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps.
Big Pharma's Looming Patents May Benefit One Biotech (01/10/2024)
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024.
Biotech Co.'s Sales Could Grow To US$310 Million in 2028 (01/10/2024)
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.
Telehealth Co. Adding Thousands to Large Contract (01/10/2024)
Reliq Health Technologies Inc. has signed a contract expansion with a large U.S. health plan, possibly adding as many as 50,000 new patients to its iUGO telehealth platform.
2024: Chen Leads With Biotech After Picking 2023's Top Stock (01/05/2024)
Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year.
Market Correction and One Cash Rich Biotech (01/03/2024)
In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value.
Boston Biotech Could Have Blockbuster Sales (01/03/2024)
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.
Pharma Co. Gets First US Patent for Repurposed Drug (01/02/2024)
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast.
California-Based Pharma Co.'s Progress Offers Upside (01/02/2024)
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.
Contracts Add Thousands of Patients to Telehealth Platform (12/28/2023)
Reliq Health Technologies Inc. says it has signed new contracts with 10 physician practices in three states to add thousands more patients to its iUGO telehealth platform.
Co.'s Breast Cancer Therapy Shows Encouraging Activity (12/28/2023)
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.
Biotech Secures Additional Funding, Extending Cash Runway (12/27/2023)
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.
Biotech Bolsters ADC Pipeline Through Atreca Asset Buy (12/26/2023)
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.
US Biotech's Anti-Fungal Wins European Approvals (12/22/2023)
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.
Biotech Co. Reports Encouraging ALS Data but FDA Wants More (12/21/2023)
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.
Pharma Co. May Have Accelerated FDA Approval in 2024 (12/20/2023)
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co.
Lithium Co. Will Be a Substantial Outperformer (12/19/2023)
Michael Ballanger of GGM Advisory Inc. shares a quick note about why he has faith in Volt Lithium Corp.
Bioscience Co. Expands Collaboration (12/19/2023)
This bioscience company's price target implies 680% upside, according to a Roth MKM report.
Promising Biotech Selling Way Under Cash Value (12/18/2023)
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater.
Texas Biotech Advances Lead Candidate in Resistant AML (12/14/2023)
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock.
Biotech Seeks Approval of Synthetic Blood Vessel Graft (12/12/2023)
Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino.
Drugs Show Anti-Cancer Effects on Myeloma Cells (12/06/2023)
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report.
Antibodies from Vaccine Remain Two Years Out (12/06/2023)
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report.
Pharma Co. Reports Positive Data for Leukemia Combination Therapy (12/06/2023)
Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report.
Massachusetts Biotech Plummets as Skin Cancer Trial Fails (12/05/2023)
In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted.
Pharma Co.'s Partnership a Key Validation (12/04/2023)
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report.
Biotech Announces New Responder in Breast Cancer Trail (11/30/2023)
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.
Biotech Receives First Approval; Drug Now Available (11/28/2023)
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.
Encouraging Early Data For Biotech's Cancer Therapies (11/21/2023)
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar.
Strong Early Launch Metrics for Biotech's Skin Disease Drug (11/20/2023)
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.
Arizona Biotech Advances Multiple Cell Therapies (11/16/2023)
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.
Massachusetts Biotech Advances Novel Cytokine Therapies (11/15/2023)
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note.
Massachusetts Biotech Presents Catalysts Into 2024 (11/08/2023)
Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.
Texas Biotech Exceeds Alzheimer's Trial Enrollment Target (11/08/2023)
This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino.
Expert Shares Thoughts on Six Stocks (11/07/2023)
Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell.
Biopharma Acquires Royalty on Approved Diabetes Drug (11/03/2023)
This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.
Survey Results Positive for New HAE Drug (11/02/2023)
Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report.
Safety Profile of New IL-2 Molecule Better Than Like Drugs' (11/02/2023)
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report.
Firm To Present Trial Results Update at SITC Meeting (11/02/2023)
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.
Add Back Positions in This Biotech (11/01/2023)
Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs.
Biotech to Advance New Type 1 Diabetes Drug Into Clinic (10/23/2023)
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report.
Approval Likely in U.S., EU for New Drug for Prader-Willi (10/12/2023)
Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report.
Drug Reform Streaming Co. Starts Trading on CSE (10/12/2023)
This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement."
Diagnostics Biotech Beats Revenue Estimates in Q3/23 (10/11/2023)
The Belgium-based company is well on its way to achieving, and possibly exceeding, full-year revenue guidance, noted an Oppenheimer report.
Chen Still Likes This Precious Metal in Q4 (10/09/2023)
If you've been following asset manager Chen Lin's quarterly picks on Streetwise Reports, you know he is bullish on one particular precious metal, and the fourth quarter of 2023 is no exception.
Trial of New Drug for Acute Leukemia Meets Primary Endpoint (10/05/2023)
The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report.
New CAR-T Therapy Shows Potency in Certain Patients (10/04/2023)
Study results for patients with relapsed/refractory multiple myeloma continue to be "favorable," noted a ROTH Capital Partners report.
New Contract Adding Thousands of Patients to Telehealth Platform (09/27/2023)
This telehealth company has signed a contract with a physician network to add as many as 100,000 patients to its platform. Find out why the CEO says it is in a period of rapid growth.
Biopharma Co. Adds CTO to Team (09/21/2023)
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.
Trial Results Validate New Drug-Delivering Nasal Implant (09/20/2023)
This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report.
Biotech Co. Makes Strides on Three Fronts (09/19/2023)
This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report.
Telehealth Co. Signs Contract With Client in Eight States (09/13/2023)
This telehealth company has signed a new contract for its remote patient monitoring platform to be used by a leading healthcare company with dozens of locations in eight states.
Telehealth Co. Expands Platform To Cover Pediatric Patients (09/08/2023)
This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum.
Co. Reaches Major Milestone With Novel Drug (09/07/2023)
The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.
Cryoablation System Gets Approved in Brazil (09/07/2023)
The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report.
After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment (09/06/2023)
Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug.
FTC Settles Suit, Potentially Averting Further Hurdles (09/06/2023)
McAlinden Research shares a deep dive into a market driver with alpha-generating potential.
Contract Adding Thousands of Patients to Co.'s Telehealth Platform (09/05/2023)
This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.
New Vaccine for Chikungunya Shown To Be Safe in Youths (09/01/2023)
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.
Approved Drug for Skin Condition Shown Safe at Higher Dose (09/01/2023)
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.
Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023 (08/31/2023)
Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into.
Catalyst Rich 12 Months Ahead for U.S. Biopharma Co. (08/29/2023)
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.
DNA Tech Co. Launches MRNA Platform and Files Two Patents (08/29/2023)
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock.
FDA Approves New Oncology Drug for Clinical Trials (08/28/2023)
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report.
Telehealth Co. Launches Monitoring Program for Acute Patients (08/18/2023)
Reliq Health Technologies Inc. has launched a new post-discharge program for acute care hospitals on its iUGO platform and signed contracts in California, Florida, and Puerto Rico.
Co. Still Undervalued Post Solid Q2/23 (08/16/2023)
The multistate operator is on a growth trend and just raised its free cash flow guidance for the year, noted a ROTH Capital Partners report.
Med Tech Firm's Q2/23 Revenue Beats Target (08/10/2023)
The company is expected to gain greater market share in one segment of its business, warranting a price target increase, noted a ROTH Capital Partners report.
Telehealth Co. Inks Contracts With Rural Clinics in 5 States, Territories (08/09/2023)
Telehealth company Reliq Health Technologies signs contracts with 20 new rural health clinics (RHCs) in California, Nevada, Puerto Rico, Texas, and the U.S. Virgin Islands.
The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside (08/07/2023)
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short.
Biotech Co. An Attractive Investment (08/04/2023)
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment.
Telehealth Co. Continues To See Soaring Revenues (08/02/2023)
This telemedicine company just had its first profitable quarter, and now it could see revenues double twice over two fiscal years.
Co. Works to Strengthen Itself After Merger Ended (08/02/2023)
Its efforts include restructuring debt and divesting assets, noted a ROTH Capital Partners report.
Merger Between Two Firms Called Off (08/02/2023)
The deal broke down because the parties could not sell assets that had to be divested for it to go through, noted a ROTH Capital Partners report.
Co. Starts Using AI on Its Telehealth Platform (07/21/2023)
This telehealth company says it has started using artificial intelligence (AI) and machine learning (ML) with two of the clients on its platform.
Second Half of 2023 Is Catalyst Rich for This Biopharma Co. (07/19/2023)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report.
Top Pick Healthcare Technology Co. Trading at Deep Discount (07/19/2023)
The healthcare tech firm's shares are underperforming despite two consecutive record quarters and a "landmark" contract win, noted an Echelon Capital Markets report.
Healthcare Tech Firm Sells Noncore Assets for $6M (07/10/2023)
The resulting upfront valuation gain equates to an estimated $0.02 per share, noted an Echelon Capital Markets report.
Approval Sought in Japan for New SARS-CoV-2 Vaccine (07/07/2023)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report.
Co. Addresses Opioid Crisis Through Novel Platforms (07/07/2023)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted.
Up to 10,000 Patients To Join Telehealth Co.s Platform in Mexico (07/06/2023)
This company is expanding its telehealth platform into Mexico, where more than 10,000 new patients are expected to be on board by next June.
New Psoriasis Drug Shown More Effective Than On-Market One (07/06/2023)
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report.
Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says (07/05/2023)
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction.
Biotech Co. Remains Opportunity for Those With High Risk Tolerance (06/30/2023)
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note.
Q3: Chen Is Still Bullish on This Precious Metal (06/29/2023)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023.
Telehealth Co. Expands to More Patients, Picks Up Coverage (06/26/2023)
Reliq Health Technologies Inc. continues to pick up more contracts with skilled nursing facilities (SNFs) and other health care groups. Now it also has gotten analyst attention.
New Drug for Bone Growth Disorder Improves Height Velocity (06/21/2023)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report.
Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries (06/16/2023)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream.
777% Gain Implied in Analyst's Target Price on Biopharma Co. (06/14/2023)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report.
Telehealth Co. Expands With Six New Contracts in Three States (06/13/2023)
New contracts are expected to add more than 3,000 new patients to Reliq Health Technologies Inc.'s platform by the first quarter of next year, the company said.
Court Grants Firm Protection From Creditors (06/12/2023)
Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report.
Biotech Co. To Exit Health Care Services (06/12/2023)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future.
Key Catalyst for US Biopharma Stock on Track for Q4/23 (06/09/2023)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report.
Medical Device Co. Completes Merger in Q1/23 (06/08/2023)
Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report.
Healthcare Tech Firm Grows Revenue 10% YOY in Q1/23 (06/05/2023)
This positive start to 2023 bodes well for the company turning EBITDA positive later this year, which is expected, noted an Echelon Capital Markets report.
FDA Approval, Private Placement Funding Buoy Biotech Firm (06/05/2023)
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement.
Telehealth Co. Notches First Profitable Quarter (06/02/2023)
Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022.
Analyst Says Pharma Co. 'Meaningfully Undervalued' (06/01/2023)
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note.
U.S. Firm's Earnings To Remain Robust Through 2023 (05/25/2023)
Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report.
Animal Feed Company Evaluating Strategic Alternatives (05/23/2023)
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit.
Wellness Co.'s Q1/23 Results Better Than Expected (05/19/2023)
Results for the first quarter of this year for Ayr Wellness Inc. were better than expected, reported an Echelon Capital Markets research note.
Telehealth Co. Signs Contract With US Health Plan Serving 1 Million Patients (05/18/2023)
Telehealth company Reliq Health Technologies signs a contract with a U.S. health plan that operates in five states with over 3,000 doctors and more than 1 million patients.
Biopharma Co. Ceases Program to Optimize Resources (05/16/2023)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report.
Digital Health Co. Grows Revenue and Reduces Expenses (05/10/2023)
This Canadian healthcare tech company is showing projected returns of over 241% for investors, noted an Echelon Capital Markets research note.
Telehealth Co. Expands into Arkansas (05/05/2023)
Telehealth company Reliq Health Technologies signs five new contracts in four states for its iUGO platform, including its first contract in the state of Arkansas, where chronic diseases cost billions annually.
Pharmaceutical Company Sets Gold Standard for New Drugs (04/26/2023)
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.
Adding Silver a Solid Move (04/24/2023)
Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market.
As Countries Bolster Defense, Opportunities Emerge (04/21/2023)
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability.
Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial (04/19/2023)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill.
Co.'s New Cell Therapy Shows Positive Effects (04/19/2023)
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report.
Blockchain Co., Vets Group Team Up for App (04/19/2023)
A Vancouver blockchain company is partnering with a leading veterans advocacy group to launch a medical cannabis education and reward application for vets.
Oncology Co. Receives Buy Rating for New Drug Trials (04/18/2023)
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report.
Biotech Rated Outperform Advances Top Drug Candidate (04/18/2023)
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report.
Trial Results of New Pneumococcal Vaccine Compelling (04/18/2023)
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report.
Follow-up Results From T2 Diabetes Trial Positive (04/14/2023)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report.
CEO: Telehealth Co. in 'More Comfortable Cash Position' (04/14/2023)
Telehealth company Reliq Health Technologies Inc. expects to be profitable for the quarter ending in June and initiate a share buyback program this year, its CEO told shareholders this week.
Biotech Co. Set To Reach New Highs (04/13/2023)
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.
Phase 3 Trial in Progress of New Ichthyosis Treatment (04/12/2023)
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report.
Biopharma Co. Appoints Industry Experts in Key Positions (04/11/2023)
Recently, Appili Therapeutics Inc. (APLI.TSX) appointed a new director of non-clinical research and director of new product development. Read to see who these people are, what upcoming catalysts there are for the company, and what experts are saying.
Phase 2b Trial of New Drug for Ovarian Cancer Starts (04/11/2023)
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report.
Safety Data From One Trial of New Drug Helpful to Another (04/05/2023)
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report.
Biotech Co. Will 'Not Look Back' From Here (04/05/2023)
In light of its recent development of a product that purportedly has the ability to reset damaged DNA, technical analyst Clive Maund takes a look at Resverlogix Corp.
Firm Grows Revenue 38% in Q4/22 (04/04/2023)
The company's material increase in profitability during the quarter is a healthy step toward reaching free cash flow break even status, noted an Echelon Capital Markets report.
Target Price on Texas-Based Drug Co. Implies 1,929% ROI (04/04/2023)
This biopharma expects two major catalysts, in the form of Phase 2 clinical trial data readouts, this year, noted a ROTH Capital Partners report.
Resverlogix Testing Cure for Covid, the Terrible Spike Protein and Heart Issues (04/03/2023)
In light of Resverlogix Corp.'s testing of a cure for long Covid, Bob Moriarty of 321gold.com reviews the company to tell you why he believes it may be a Buy.
New Treatment for Ovarian Cancer Shows Promise (03/30/2023)
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report.
Telehealth Co. Signs Largest Client Yet (03/30/2023)
Onboarding will begin in April for the healthcare system that has more than 1,200 care centers in seven states.
Coverage Launched on Drug Co. With 140% Upside (03/29/2023)
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report.
Trial of New Ophthalmic Drug Now Enrolled (03/29/2023)
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report.
FDA Approval of New Gout Drug Likely, Analyst Says (03/27/2023)
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report.
Biotech Improves Efficiency of Its New Immunotherapy (03/22/2023)
The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report.
Former NFL Safety Director Joins Neurotherapy Firm Advisory Board (03/21/2023)
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.
Coverage Launched on Canadian Specialty Pharma Co. (03/15/2023)
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report.
Telemedicine Co. Sees Record Revenues on Software, Services Sales (03/13/2023)
Reliq Health Technologies Inc. reports that software and services revenue continues to increase, leading to record cash intake for the quarter that ended Dec. 31, 2022.
Blockchain Co. Launches Digital Coupon Consumer App (03/08/2023)
Global Compliance Applications Corp. is launching a new app that will enable consumers to receive and share digital token coupons and store them in digital wallets.
New Skin Gene Therapy Gets PDUFA Date (03/01/2023)
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report.
Novel Therapy Corp Captures More of US Licensing Market, First EU Segment (02/28/2023)
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream.
AI-Infused Telehealth Platform Absorbs New Patients (02/22/2023)
Telemedicine company Reliq Health Technologies Inc., which uses artificial intelligence in its software's algorithms, has gained six new contracts and more than 3,000 new patients.
Biotech Co. Initiates Feasibility Study (02/09/2023)
This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn.
Addiction Therapy Company Secures Major UK Endorsement (02/07/2023)
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region.
New Drug for Hearing Loss Approved for Clinical Trials (01/30/2023)
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.
Biopharma Gains Another Shot on Goal With IND Approval (01/26/2023)
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.
Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus (01/25/2023)
Streetwise Reports sat down with Øyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus.
Med Tech Co. Well-Poised for Revenue Growth This Year (01/25/2023)
New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report.
Biopharma Creating COVID Drug Gets US$8.2M From the DOD (01/24/2023)
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.
Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment (01/24/2023)
Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.
Exploring Why The Economist Named this Biotech 'One To watch' in 2023 (01/23/2023)
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.
Telehealth Co. Expects More Growth in 2023 (01/20/2023)
Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program.
Biopharma Co.'s Burn Tissue Removal Product Approved (01/04/2023)
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.
Which Precious Metal Has Chen Excited for 2023? (12/28/2022)
It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year?
Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio (12/28/2022)
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.
Target Price Boosted 400% on Biopharma Co. (12/27/2022)
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.
Biotech at Good Entry Point for Investors, Analyst Says (12/20/2022)
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Data on New Cell Therapy for LBCL Encouraging, Analyst Says (12/16/2022)
The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report.
Why One Fund Owns 13% of This Small-Cap Pharma (12/12/2022)
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
Biotech Co. Signs US$735M Deal (12/09/2022)
Entrada Therapeutics Inc. shares traded 18.5% higher yesterday after the company reported it entered a global development collaboration with Vertex Pharmaceuticals Inc. to develop cutting-edge intracellular Endosomal Escape Vehicle (EEV™) therapeutics for use in treating myotonic dystrophy type 1.
Biopharma Co.'s Shares Triple in Value on US$5B License Deal (12/07/2022)
Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-license agreement with Akeso Inc. for its breakthrough bispecific antibody ivonescimab, which combines a blockade of PD-1 with an anti-VEGF into a single molecule designed to target cancer. Summit has agreed to pay Akeso an upfront payment of US$500 million, which it plans to finance via an equity rights issuance.
Biotech Co.'s Shares Soar to New 52-Week High (12/07/2022)
Prometheus Biosciences Inc. shares traded 170% higher to a new 52-week intraday high after the company reported positive results from two separate Phase 2 clinical studies for its PRA023, an anti-TL1A mAb used to treat inflammatory bowel disease. The company is actively planning to advance PRA023 into Phase 3 trials as a prospective treatment for ulcerative colitis and Crohn's disease in FY/23.
Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial (12/05/2022)
Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.
Target Price Boosted on Canadian Pharma Co. (11/30/2022)
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.
Biopharma Co. Now at a Bargain Price, Analyst Says (11/29/2022)
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.
Major Contract and Faster Commercialization for Chemicals Co. (11/29/2022)
Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.
Expert Says Health Tech Co. Still in Good Spot To Buy (11/28/2022)
Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.
Biopharma Co. Trades to New 52-Week High (11/28/2022)
Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial.
Pharma Co. Gains Approval for SARS-CoV-2 Drug (11/23/2022)
Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.
Life Sciences Co. Exceeds Expectations in Q3/22 (11/22/2022)
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.
Q4/22 Catalysts Could Boost Undervalued Biopharma Stock (11/22/2022)
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.
Global Drug Co. Offers US$1.35B To Boost Hematology Assets (11/22/2022)
Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.
Blockchain Co. Signs Agreement With Insurance Co. (11/22/2022)
Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.
FDA Awards Breakthrough Therapy Status for AMD Drug (11/21/2022)
Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.
Pharma Co. Won't See Bump in Sales From New COVID Drug (11/18/2022)
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.
Biopharma Co. Hopes To Turn US$30M Into US$2B (11/17/2022)
CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.
Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data (11/16/2022)
4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.
Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment (11/14/2022)
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.
UK Co. Buys NARCAN® Nasal Spray Maker (11/14/2022)
Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.
US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says (11/11/2022)
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.
Biologics Co. Doubles Revenue in Q3/22 (11/11/2022)
ADMA Biologics Inc. shares traded 27.5% higher yesterday after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.
Pharma Co. Trades 200% Higher (11/10/2022)
Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.
Medical Device Co.'s Q2/22 Results Better Than Expected (11/09/2022)
Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report.
Nine Stocks Expert Says Should Pique Your Interest (11/09/2022)
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.
Clean Nuclear Med Tech With Quantum Blue Sky (11/09/2022)
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.
Healthcare Firm Offers US$295M for Ophthalmology Co. (11/08/2022)
Shares of Oyster Point Pharma Inc. traded 38.5% higher yesterday after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.
Pharma Co. Signs Global License Deal for Eye Drops (11/08/2022)
Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances.
Organ Transplant Co.'s Q3 Revenues Rise 378% (11/04/2022)
Shares of medical technology firm TransMedics Group Inc. traded 24% higher to a new 52-week high after the company reported Q3/22 financial results highlighting a 378% YoY increase in net revenue and raised its FY/22 revenue estimates to US$80-85 million.
Telemedicine Co. Surges on Revenue News (11/04/2022)
As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.
San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines (11/03/2022)
Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide.
Pharma Co. Earns Big Rewards from Global License Deal (11/02/2022)
Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
